HydRIS Vaccine Stability Device Could Revolutionize Cold-Chain Requirements

Published on: 

Nova Bio-Pharma Technologies' new vaccine stability device eliminates the need for cold storage.

To remain stable for prolonged periods of time, most vaccines need to be kept cold throughout the supply chain. Nova Bio-Pharma has announced that the company has secured a patent that could change the way vaccines are stored and distributed in the future.

The new patent is for Hypodermic Rehydration Injection System (HydRIS), a vaccine stabilization device that allows pharmaceuticals to be dried and affixed onto a fibrous membrane, keeping them stable over ambient temperatures. The membrane is housed in a container that can attach to a needle and syringe. When the vaccine is to be administered, liquid in the syringe is flushed through the device, rehydrating the vaccine’s active ingredient.

HydRIS will allow delicate and perishable pharmaceutical products to remain viable at elevated temperatures without the risk of product degradation. This technology could eliminate much of the waste associated with vaccines that are ruined as a result of improper storage, and could help cut the high costs linked to cold-chain operations.


The rehydration technique could extend to oral and topical products in the future, noted Sam de Costa, stabilization project manager at Nova Bio-Pharma Technologies. “The market is seeking new forms of drug delivery to improve all stages of its lifecyle—from manufacture to administration and storage,” he said in a press release. “We are engaged in many projects to develop new products or re-invigorate older ones looking to extend their value, and this patent offers added security for those seeking to invest in new technologies with us.”

Source: www.novalabs.co.uk